Referred to the House Committee on Ways and Means.
This bill amends the Harmonized Tariff Schedule of the United States to add two new subheadings: one in chapter 39 for silicone prosthetic breast forms used with mastectomy bras, and one in chapter 90 for mastectomy brassieres. Both new subheadings show a general rate of duty of 0% and list specified countries with a “Free” special rate; the bill text also lists additional column rates (25% for the prosthetic forms, 90% for mastectomy bras).
Priority: access and health equity (left) versus protecting domestic industry (right)
Relative to its intended legislative type, this bill is a narrowly tailored and concrete amendment to the Harmonized Tariff Schedule: it provides precise statutory language, tariff numbers, duty rates, and an effective date suitable for immediate administrative implementation.
This bill amends the Harmonized Tariff Schedule of the United States to add two new subheadings: one in chapter 39 for silicone prosthetic breast forms used with mastectomy bras, and one in chapter 90 for mastectomy brassieres.
Both new subheadings show a general rate of duty of 0% and list specified countries with a “Free” special rate; the bill text also lists additional column rates (25% for the prosthetic forms, 90% for mastectomy bras).
The changes take effect for goods entered or withdrawn for consumption on or after January 1, 2027.
A narrow, low-cost, compassionate-sounding tariff change typically has reasonable odds, but passage depends on fit into legislative schedule or a trade package.
Relative to its intended legislative type, this bill is a narrowly tailored and concrete amendment to the Harmonized Tariff Schedule: it provides precise statutory language, tariff numbers, duty rates, and an effective date suitable for immediate administrative implementation. It does not address fiscal impacts, include detailed product definitions, or provide post-enactment review or oversight.
Priority: access and health equity (left) versus protecting domestic industry (right)
These are examples from the analysis, not a ranked list of the most-affected groups.
Priority: access and health equity (left) versus protecting domestic industry (right)
Likely broadly supportive because the change reduces import duties on medical items for breast cancer survivors, improving affordability and access.
The persona would welcome the targeted tariff relief as a modest health-equity measure, while noting it does not by itself address insurance coverage or domestic production concerns.
Generally favorable but pragmatic and cautious: a narrow tariff change for medical goods seems reasonable, yet details matter.
The centrist will want clear product definitions, a modest assessment of revenue impact, and monitoring to ensure benefits reach survivors.
Mixed to somewhat skeptical: sympathetic to lowering barriers for medical needs, but wary of creating tariff carve-outs and weakening domestic manufacturing.
The persona will focus on precedent, fiscal effects, and protecting U.S. industry.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
A narrow, low-cost, compassionate-sounding tariff change typically has reasonable odds, but passage depends on fit into legislative schedule or a trade package.
The bill has not accumulated any surfaced votes yet.
Priority: access and health equity (left) versus protecting domestic industry (right)
A narrow, low-cost, compassionate-sounding tariff change typically has reasonable odds, but passage depends on fit into legislative schedul…
Relative to its intended legislative type, this bill is a narrowly tailored and concrete amendment to the Harmonized Tariff Schedule: it provides precise statutory language, tariff numbers, duty rates, and an effective…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.